[1] Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016;20:205-214.
[2] WANG C L,LIANG L,FU J F,et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol,2008,14:1598-1602.
[3] 宿世震,项东宇,刘晓庆,等. 布渣叶对非酒精性脂肪性肝病小鼠的作用及机制. 中国实验方剂学杂志,2017,24:130-135.
[4] 杨将领,张 斌.抗脂方改善大鼠非酒精性脂肪性肝炎的实验研究.上海中医药杂志,2017,51:84-90.
[5] 侯洪涛,裘艳梅,冯佳,等.姜黄素对非酒精性脂肪性肝病大鼠肠道SIgA及氧化应激的影响.广东医学,2017,39:1133-1136.
[6] Song CY1, Zeng X, Chen SW,et al.Sophocarpine alleviates non-alcoholic steatohepatitis in rats.J Gastroenterol Hepatol, 2011,26:765-74.
[7] Buzzetti E, Pinzani M, Tsochatzis EA. The multi- ple-hit pathogenesis of non-alcoholic fatty liver disease ( NAFLD). Metabolism, 2016, 65:1038-1048 .
[8] A. Bujold and L. A. Dawson.Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma.Cancer/Radiothérapie,2011,15:54-63.
[9] Y. Zhang, S. Wang, Y. Li, et al. Sophocarpine and matrine inhibit the production of TNF-α and IL-6 in murine macrophages and prevent cachexiarelated symptoms induced by colon26 adenocarcinoma in mice. International Immunopharmacology,2008,8:1767-1772.
[10] Y. Gao, W. Jiang, C. Dong, et al.Anti-inflammatory effects of sophocarpine in LPS-induced RAW 264.7 cells via NF-κB and MAPKs signaling pathways. Toxicology In Vitro, 2012,26:1-6.
[11] Park EJ, Lee JH, Yu G, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010, 40:197-208.
[12] De Minicis S, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC:Pathogenetic mechanisms and therapeutic insights. Curr Pharmaceut Des,2013,19:5239-5249. |
